<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398681</url>
  </required_header>
  <id_info>
    <org_study_id>MYOCARDIAL-IRON</org_study_id>
    <secondary_id>2016-004194-40</secondary_id>
    <nct_id>NCT03398681</nct_id>
  </id_info>
  <brief_title>Changes in Myocardial Iron After Iron Administration</brief_title>
  <official_title>Changes in Myocardial Iron Content Following Administration of Intravenous Iron (Myocardial-IRON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have shown that treatment with intravenous iron in patients with iron
      deficiency (ID) and heart failure with reduced ejection fraction (HFrEF) improves
      symptomatology, functional capacity, quality of life, and decreases hospitalizations
      regardless of anemia. In addition, a decrease in myocardial iron content has been observed in
      patients with chronic HFrEF. This preliminary evidence has led to postulate that myocardial
      iron deficiency could play a direct role in the pathogenesis and progression of the disease.

      The investigators hypothesize that the repletion of myocardial iron would explain part of the
      benefit of this treatment. Thus, the investigators postulate that cardiac magnetic resonance
      (CMR) (T2* and T1-mapping sequences) will be sensible enough to detect changes in myocardial
      iron content as a result of intravenous iron administration, and that such changes will
      correlate with simultaneous changes in parameters of heart failure severity.

      In this double-blind 1:1 randomized study controlled by placebo the investigators aim to
      determine the changes in myocardial iron content after treatment with intravenous ferric
      carboxymaltose (FCM) by CMR at 7 and 30 days in patients with stable HFrEF and ID.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After providing informed consent, patients will be randomly assigned, with a remote, web-based computer-generated block randomization procedure in an allocation 1:1 ratio, to either receive intravenous ferric carboxymaltose (FCM) or placebo. Intramyocardial iron will be evaluated at 3 time points: before administration of CMF/placebo, and at 7 and 30 days. At 30 days, patients assigned to placebo will receive intravenous CMF if iron deficiency persists.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Because ferric carboxymaltose is a dark-brown solution that is easily distinguishable from the saline placebo, study personnel responsible for the preparation and administration of the study drug will aware of the group assignments and therefore, not involved in any study assessments. To ensure that patients will be unaware of the study drug, materials used in drug administration will be covered with aluminum foil or other opaque material and the injection site shield from the patient view. Once treatment is allocated, the investigators team will ensure that patients are blinded to the treatment received.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in myocardial iron content assessed by CMR T2*</measure>
    <time_frame>7 and 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in myocardial iron content assessed by CMR T1-mapping</measure>
    <time_frame>7 and 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular systolic function evaluated with cardiac magnetic resonance</measure>
    <time_frame>7 and 30 days</time_frame>
    <description>Changes in left ventricular systolic function evaluated with cardiac magnetic resonance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walking test</measure>
    <time_frame>7 and 30 days</time_frame>
    <description>Changes in functional capacity assessed by distance walked in 6 minutes (6-minute walking test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) class.</measure>
    <time_frame>7 and 30 days</time_frame>
    <description>Changes in functional capacity assessed by New York Heart Association (NYHA) class.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Kansas City quality of life questionnaire (KCCQ)</measure>
    <time_frame>7 and 30 days</time_frame>
    <description>Quality of life assessed by The Kansas City quality of life questionnaire (KCCQ). KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigen carbohydrate 125 (CA125)</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests, biomarkers: antigen carbohydrate 125 (CA125)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino-terminal pro-brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests, biomarkers: amino-terminal pro-brain natriuretic peptide (NT-proBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Galectin-3</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests, biomarkers: galectin-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-2</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests, biomarkers: ST-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity troponin (hsTnT)</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests, biomarkers: high-sensitivity troponin (hsTnT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests, biomarkers: cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil gelatinase-associated lipocalin (NGAL)</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests, biomarkers: neutrophil gelatinase-associated lipocalin (NGAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: urea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: estimated glomerular filtration rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation (TSAT)</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: transferrin saturation (TSAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>soluble transferrin receptor (sTfR)</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: soluble transferrin receptor (sTfR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin</measure>
    <time_frame>30 days</time_frame>
    <description>Laboratory tests: hepcidin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events: all-cause hospitalizations</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events: cardiovascular hospitalizations.</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiovascular hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events: heart failure hospitalizations.</measure>
    <time_frame>30 days</time_frame>
    <description>Heart failure hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events: time to first hospitalization for any reason.</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first hospitalization for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events: time to first hospitalization for any cardiovascular reason.</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first hospitalization for any cardiovascular reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events: time to first hospitalization due to worsening heart failure.</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first hospitalization due to worsening heart failure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Intravenous ferric carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboymaltose</intervention_name>
    <description>Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)]</description>
    <arm_group_label>Intravenous ferric carboxymaltose</arm_group_label>
    <other_name>Ferinject, intravenous iron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Normal saline)</intervention_name>
    <description>Normal saline (0.9% weight/volume (w/v) NaCl)</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac magnetic resonance</intervention_name>
    <description>Cardiac magnetic resonance including T2* and T1-mapping sequences</description>
    <arm_group_label>Intravenous ferric carboxymaltose</arm_group_label>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ambulatory chronic heart failure

          -  Older than 18 years

          -  Patients in NYHA class II-III on optimal background therapy (as determined by the
             investigator) for at least 4 weeks with no dose changes of HF drugs during the last 2
             weeks (with the exception of diuretics)

          -  Elevated natriuretic peptides levels (NT-proBNP &gt;400 pg/ml) at the screening visit

          -  Left ventricle ejection fraction &lt;50% documented in the last 12 months

          -  Iron deficiency defined as: serum ferritin level &lt;100 μg/L or ferritin level 100-299
             μg/L when TSAT is less than 20%, and hemoglobin &lt;15 g/dL (all at screening)

          -  Participant is willing and able to give informed consent for participation in the
             study

        Exclusion Criteria:

          -  Known sensitivity to any of the products to be administered per protocol.

          -  History of acquired iron overload.

          -  Severe valve disease, or being scheduled for cardiac surgery within the next 30 days.

          -  Acute myocardial infarction or acute coronary syndrome, transient ischemic attack, or
             stroke within the last 3 months prior to randomization.

          -  Coronary artery bypass graft, percutaneous intervention (e.g. cardiac,
             cerebrovascular, and aortic; diagnostic catheters are allowed), or major surgery,
             including thoracic and cardiac surgery, within the last 3 months prior to
             randomization.

          -  Ischemic heart disease scheduled for revascularization procedures within the next 30
             days.

          -  HF scheduled for cardiac resynchronization therapy within the next 30 days.

          -  Patients with active bleeding in the last 30 days.

          -  Known active infection or active malignancy.

          -  Subject at an immediate need of transfusion or hemoglobin ≥15 g/dL.

          -  Anemia due to reasons other than iron deficiency

          -  Immunosuppressive therapy or renal dialysis

          -  History of erythropoietin, intravenous iron therapy, and blood transfusion in the
             previous 12 weeks.

          -  Oral iron therapy at doses &gt;100 mg/day in previous 1 week prior to randomization.

          -  Subjects with an immediate need for transfusion.

          -  Pregnant or breastfeeding women.

          -  Subject of childbearing potential who is not willing to use adequate contraceptive
             precautions during the study and for up to 5 days after the last scheduled dose of
             study medication.

          -  Subject currently enrolled in or has not yet completed at least 30 days since ending
             other investigational device or drug study, or subject is receiving other
             investigational agent(s).

          -  Any kind of disorder that compromises the ability of the subject to give written
             informed consent and/or to comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Nuñez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Investigación Hospital Clínico Universitario de Valencia. Instituto de Investigación Sanitaria INCLIVA.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julio Nuñez, MD PhD</last_name>
    <phone>652856689</phone>
    <email>yulnunez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid Cardells, MD</last_name>
    <phone>660619422</phone>
    <email>ingridcb88@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de Castellón</name>
      <address>
        <city>Castellón De La Plana</city>
        <state>Castellón</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Palau, MD PhD</last_name>
      <email>patripalau@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Palau, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Llacer, MD PhD</last_name>
      <email>paullaceriborra@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pau Llacer, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ERESA</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pilar Lopez Lereu, MD PhD</last_name>
      <email>plereu@eresa.com</email>
    </contact>
    <contact_backup>
      <last_name>Jose Vicente Monmeneu, MD PhD</last_name>
      <email>jmonmeneu@eresa.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fundación Investigación Hospital Clínico Universitario de Valencia. Instituto de Investigación Sanitaria INCLIVA.</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Nuñez, MD PhD</last_name>
      <phone>652856689</phone>
      <email>yulnunez@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid Cardells, MD</last_name>
      <phone>660619422</phone>
      <email>ingridcb88@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Julio Nuñez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gema Miñana, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingrid Cardells, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernesto Valero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Santas, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio García-Blas, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Mollar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amparo Villaescusa, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Rodriguez, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael De la Espliella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Fácila, MD PhD</last_name>
      <email>lfacila@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Fácila, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Almenar, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Almenar, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Julio Nuñez</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Cardiac magnetic resonance</keyword>
  <keyword>Ferric carboxymaltose</keyword>
  <keyword>Myocardial iron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

